Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $88000.0.

  • Protagonist Therapeutics' Capital Expenditures fell 8857.14% to $88000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 6503.76%. This contributed to the annual value of $1.4 million for FY2024, which is 12249.59% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Capital Expenditures stood at $88000.0 for Q3 2025, which was down 8857.14% from $813000.0 recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Capital Expenditures ranged from a high of $813000.0 in Q2 2025 and a low of $15000.0 during Q1 2023
  • Moreover, its 5-year median value for Capital Expenditures was $242000.0 (2024), whereas its average is $279263.2.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9450.55% in 2023, then skyrocketed by 236363.64% in 2025.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Capital Expenditures stood at $196000.0 in 2021, then tumbled by 64.29% to $70000.0 in 2022, then tumbled by 72.86% to $19000.0 in 2023, then skyrocketed by 1531.58% to $310000.0 in 2024, then tumbled by 71.61% to $88000.0 in 2025.
  • Its last three reported values are $88000.0 in Q3 2025, $813000.0 for Q2 2025, and $545000.0 during Q1 2025.